An ultra-sensitive and cost-effective diagnostic to improve AML patient outcome.

Time period: 2019-07-01 to 2021-06-30

Project leader: Ulf Landegren

Funder: Vinnova

Type of award: Project grant

Total fundning: 2 200 000 SEK

Purpose and goal: Highly sensitive and accurate assays are needed to monitor patients with acute myeloid leukemia (AML), receiving targeted therapies. Early signs of resistance to the therapy can be met with alternate drugs. We will demonstrate that the ultrasensitive sRCA technique, earlier than competing techniques, can sense the presence of mutations heralding therapy resistance, providing a more beneficial treatment outcome. The technology can be generalized to most other malignancies. Expected results and effects: The project will validate the sRCA technique for detection of therapy-resistant mutations for AML patients at improved sensitivity compared to competing techniques. We will also demonstrate the suitability of the sRCA technique in a clinical setting in term of assay flexibility, robustness, handling time, work load, etc. Approach and implementation: In the University lab we will design and establish sRCA assays for therapy-resistant mutations in AML, and validate the assays as well as the entire work-flow using standard samples. Once the assays reach the desired performance and robustness they will be transferred to the clinical genetics lab at Uppsala University Hospital to analyze patient samples, benchmarking the technique against competing approaches in term of performance and work flow. We will evaluate the business opportunities of this new technology.